Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
8 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
8
Trials led
0
Ongoing
4,446
Total enrollment
379
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
4
Phase 3
3
Not applicable
1
Trials by status
Completed
4
Terminated
4
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)Alzheimer's diseasePh 3Completed1,331
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)Alzheimer's diseasePh 3Completed1,121
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 3Terminated896
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Diseasemild-to-moderate ADPh 2Terminated375
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's DiseaseStudy partner/caregiver requiredPh 2Terminated194